BeiGene (HKG:6160, SHA:688235) recorded a net income of $1.3 million in the first quarter, compared with a net loss of $251.2 million in the year-ago period, a Wednesday Hong Kong bourse filing said.
The company did not make any earnings per share in the three months, while it had incurred a loss per share of $0.19 in the corresponding period of the last year.
Revenue for the pharmaceutical company rose 49% to $1.12 billion in the quarter from $751.7 million a year prior, driven primarily by higher product sales under the BRUKINSA brand in the US and Europe.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。